3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is a popular recreational drug. The study aim was to explore the role of dopamine in the psychotropic effects of MDMA using bupropion to inhibit the dopamine and norepinephrine transporters through which MDMA releases dopamine and norepinephrine. The present study investigated the pharmacodynamic and pharmacokinetic interactions between bupropion and MDMA in 16 healthy subjects using a double-blind, placebo-controlled, crossover design. Bupropion 
Introduction
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is a popular recreational drug that acts by releasing dopamine (DA), norepinephrine (NE), and serotonin (5-HT) through their corresponding transporters (Verrico et al., 2007; Hysek et al., 2012d ). The present study was designed to contribute to the elucidation of the mechanism of action of MDMA in humans. Specifically, we explored the modulatory role of DA in the psychotropic effects of MDMA using bupropion pretreatment to block MDMA-induced DA release. Dopamine transporter inhibition prevents the release of DA through the DA transporter induced by MDMA or other amphetamines (Verrico et al., 2008; Simmler et al., 2013b) .
The averages were calculated for the analyses.
Pupillometry. Pupillometry was performed 2 and 1 h before and 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6 , and 8 h after drug administration. Pupil function was measured using a PRL-200 infrared pupillometer (NeurOptics, Irvine, CA; under dark-light conditions of 6.1 ± 1 lux as described previously (Hysek and Liechti, 2012) . The dark-adapted pupil diameter was measured in both eyes, and the average values were used for analyses.
Endocrine measures. Plasma levels of prolactin and cortisol were measured at baseline and 2 h after MDMA or placebo administration using radioimmunoassays (Hysek et al., 2012b) . Plasma levels of oxytocin were measured before and 1 and 2 h after administration of MDMA or placebo by radioimmunoassay (Neumann et al., 2013) .
Concentrations of circulating catecholamines, including epinephrine and NE, were measured at baseline and 1 and 2 h after administration of MDMA or placebo using ultra performance liquid chromatography-tandem mass spectrometry (Dunand et al., 2013) . Plasma epinephrine levels are mainly derived from the adrenal medulla, whereas the entrance of NE into the plasma represents an overflow by sympathetic nerves (Esler et al., 1990; Eisenhofer et al., 1995) . Circulating NE is therefore considered an indicator of sympathetic system activation. DA in plasma does not derive from DA but mostly from NE neurons (Goldstein and Holmes, 2008) . Nevertheless, we measured DA levels in plasma because there are no data on the effects of MDMA on DA plasma levels.
Adverse effects. Adverse effects were assessed using the 66-item List of Complaints (Zerssen, 1976) before and 5 and 24 h after MDMA or placebo administration. The scale yields a total adverse effects score, reliably measuring physical and general discomfort.
Psychometric scales. Subjective effects were repeatedly assessed using previously described psychometric scales. Visual Analog Scales (VASs; (Hysek et al., 2011) ) were administered 2 and 1 h before and 0, 0. 33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 , and 24 h after administration of MDMA or placebo.
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Pharmacokinetics. Blood samples for the determination of MDMA, MDA, HMMA, bupropion, hydroxybupropion, and hydrobupropion were collected 2 h before and 0, 0. 33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , and 24 h after MDMA or placebo administration. Plasma MDMA, MDA, and HMMA concentrations were determined using high-performance liquid chromatography-masspectrometry/masspectrometry as described previously (Hysek et al., 2012a; Hysek et al., 2013) . Bupropion, hydroxybupropion, and hydrobupropion were included into the analytical method and slight modifications were made. In brief, the chromolith speedROD RP-18e (50 × 4.6 mm, Merck, Darmstadt, Germany) analytical column was replaced by a luna PFP (2) column (50 × 2 mm, Phenomenex, Torrance, USA), and bupropion, hydroxybupropion, and hydrobupropion were added as additional analytes. Peak symmetry was improved by online dilution of the samples with water supplemented with 0.1% formic acid. Threohydrobupropion and erythrohydrobupropion were quantified together as hydrobupropion because the isomeric metabolites co-eluted in chromatography and were indistinguishable in mass spectrometry. The performance of the method was monitored using quality control samples at the lower limit of quantification (LLOQ) and at 2-4 other concentrations that covered the entire calibration range. The LLOQ values were 1 ng/ml for MDMA, MDA, HMMA, and hydroxybupropion, 5 ng/ml for bupropion, and 0.1 ng/ml for hydrobupropion. The inter-assay precision was < 15% (LLOQ: 20%), and the inter-assay accuracy ranged from 85% to 115% (LLOQ: 80-120%) for all of the analytes.
Statistical and pharmacokinetic analyses
Peak effects (E max ) and peak changes from baseline (ΔE max (AUEC) were calculated using the linear trapezoidal rule.
Results

Autonomic effects
Peak effects and statistics are summarized in Table 2 . MDMA increased blood pressure, heart rate, and body temperature ( Fig. 1a-d ). Bupropion significantly reduced the MDMA-induced increase in heart rate ( Fig. 1c ) but did not significantly affect the increases in blood pressure (Fig. 1a, b) or body temperature ( Fig. 1d ) induced by MDMA. Bupropion did not alter the mydriatic effect of MDMA on pupillary function (Table 2) .
Endocrine effects
MDMA increased plasma concentrations of prolactin, cortisol, oxytocin, epinephrine, and NE compared with placebo. Bupropion significantly reduced the MDMA-induced increases in the plasma concentrations of NE but not other hormones (Table 2) . Plasma levels of DA were very low and in 75% of the measurements below the lower limit of detection (<0.1 nM). None of the treatments altered DA plasma concentrations.
Adverse effects
The acute (up to 5 h) and subacute (up to 24 h) adverse effects of MDMA were not altered by bupropion (Table 2 ). Frequently reported acute adverse effects of placebo-MDMA and bupropion-MDMA were lack of appetite (n = 13 for both), perspiration (n = 11 and 12, respectively), tremor (n = 8 and 11, respectively), restlessness (n = 10 and 7, respectively), dry mouth (n = 14 and 12, respectively), and bruxism (n = 13 for both). Subacute adverse effects included headache (n = 12 and 8, respectively), tiredness (n = 9 and 10, respectively), lack of appetite (n = 8 and 9, respectively), difficulty concentrating (n = 7 and 6, respectively), dry mouth (n = 5 and 9, respectively), and bruxism (n = 6 and 10, respectively).
No severe adverse effects were reported.
Subjective effects
Peak effects and statistics are summarized in Table 2 . MDMA increased VAS ratings for "any drug effect," "good drug effect," "drug high," "drug liking," and "stimulated" (Fig. 2a-e ). Bupropion enhanced the positive mood effects of MDMA, reflected by a significant increase in AUEC values and nonsignificant increase in maximal effect ratings, in the bupropion-MDMA condition compared with the placebo-MDMA condition for VAS scales ratings for "any drug effect," "good drug effect," "drug high," and "drug liking" (Table 2 , Fig.   2a-d) . MDMA-induced increases in "stimulation" were not significantly altered by bupropion (Fig. 2e ).
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Pharmacokinetics
The drug and metabolite concentration-time curves are shown in Fig. 3 . The pharmacokinetic parameters are shown in Table 3 . Bupropion pretreatment significantly increased the plasma concentration of MDMA (C max, p < 0.01; AUC 0-8 , p < 0.001; AUC 0-24, p < 0.001) and prolonged its t 1/2 (p < 0.01). In contrast, bupropion pretreatment significantly decreased the plasma concentrations of MDA (C max , p < 0.01; AUC 0-8, p < 0.001) and HMMA (C max, p < 0.001; AUC 0-8, p < 0.001; AUC 0-24, p < 0.001) and prolonged the t 1/2 and T max of HMMA (both p < 0.001). MDMA significantly increased the plasma concentration of bupropion (C max, p < 0.05; AUC 0-8, p < 0.001; AUC 0-24, p < 0.01). MDMA also slightly increased the C max of hydrobupropion (p < 0.05) but had no effect on the concentration of hydroxybupropion.
The MDMA concentration-effect plot (Fig. 4.) shows that higher subjective effects were reached early during the drug response in the bupropion-MDMA condition compared with the placebo-MDMA condition at similar MDMA concentrations consistent with a dynamic drug interaction. Thus, bupropion did not reduce the MDMA response taking into account any pharmacokinetic interactions.
Discussion
In the present study, bupropion reduced the heart rate response to MDMA and prolonged its subjective effects. We hypothesized that bupropion prevents the pharmacodynamic effects of MDMA to the extent that these effects depend on DA and NE release. Bupropion reduced the MDMA-induced increases in circulating NE which is a marker of sympathetic system activation and the cardiostimulant effects of MDMA similarly to the selective NE transporter inhibitor reboxetine (Hysek et al., 2011) . The blockade of α -and β -adrenergic receptors by carvedilol reduced the heart rate and blood pressure response to 
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